Time-trend analysis on the Framingham risk score and prevalence of cardiovascular risk factors in patients undergoing percutaneous coronary intervention without prior history of coronary vascular disease over the last 17 years: A study from the mayo clinic PCI registry

Clinical Cardiology

Volumn 37, Issue 7, 2014, Pages 408-416

  Lee, Moo Sik ^a,b   Flammer, Andreas J ^a   Li, Jing ^a   Lennon, Ryan J ^a   Singh, Mandeep ^a   Holmes, David R ^a   Rihal, Charanjit S ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b Konyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE REGISTRY; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GROWTH; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIMARY PREVENTION; SMOKING; TIME; TREND STUDY; ADVERSE EFFECTS; AGE; BLOOD; CORONARY DISEASE; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; TREATMENT OUTCOME; TRENDS; UNITED STATES;

AGE DISTRIBUTION; AGE FACTORS; AGED; BLOOD PRESSURE; BODY MASS INDEX; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; MINNESOTA; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SMOKING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904725031     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22274     Document Type: Article

References (27)

1. Arnett DK, McGovern PG, Jacobs DR Jr, et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol. 2002; 156: 929-935.
2. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States. Circulation. 2000; 102: 3137-3147.
3. American Heart Association. 2003 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2004.
4. Kannel WB, Vasan RS,. Adverse consequences of the 50% misconception. Am J Cardiol. 2009; 103: 426-427.
5. Khawaja FJ, Rihal CS, Lennon RJ, et al. Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients <50 years of age having percutaneous coronary intervention. Am J Cardiol. 2011; 107: 668-674.
6. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117: 743-753.
7. Germino FW,. JNC 8: Expectations, challenges, and wishes-a primary care perspective. J Clin Hypertens (Greenwich). 2009; 11: 573-576.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP). Bethesda, MD: National Heart, Lung, and Blood Institute; 2002. NIH publication no. 02-5215.
9. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003; 289: 2560-2572.
10. Roger VL, Go AS, Lloyd Jones DM, et al; Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125: e1002.
11. National Center for Health Statistics, Centers for Disease Control and Prevention, US Department of Health and Human Services. Health, United States 2010, 2011.
12. Tsang TS, Barnes ME, Gersh BJ, et al. Risks of coronary heart disease in women: current understanding and evolving concepts [published correction appears in Mayo Clin Proc. 2001;76:348]. Mayo Clin Proc. 2000; 75: 1289-1303.
13. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update [published correction appears in Circulation. 2006;113:e847]. Circulation. 2006; 113: 2363-2372.
14. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005; 293: 1868-1874.
15. Gandhi GY, Roger VL, Bailey KR, et al. Temporal trends in prevalence of diabetes mellitus in a population-based cohort of incident myocardial infarction and impact of diabetes on survival. Mayo Clin Proc. 2006; 81: 1034-1040.
16. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952.
17. Critchley JA, Capewell S,. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003; 290: 86-97.
18. Pizacani BA, Martin DP, Stark MJ, et al. Household smoking bans: which households have them and do they work? Prev Med. 2003; 36: 99-107.
19. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009; 120: 212-220.
20. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31: 1142-1148.
21. Takumi T, Mathew V, Barsness GW, et al. The association between renal atherosclerotic plaque characteristics and renal function before and after renal artery intervention. Mayo Clin Proc. 2011; 86: 1165-1172.
22. Reriani MK, Flammer AJ, Jama A, et al. Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J. 2012; 76: 778-783.
23. Perschbacher JM, Reeder GS, Jacobsen SJ, et al. Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community. Mayo Clin Proc. 2004; 79: 983-991.
24. Lindholm LH, Carlberg B, Samuelsson O,. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366: 1545-1553.
25. Bielecka-Dbrowa A, Aronow WS, Rysz J, et al. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010; 8: 733-741.
26. Coleman CI, Baker WL, Kluger J, et al. Agency for Healthcare Research and Quality. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Rockville, MD: Agency for Healthcare Research and Quality; October 2009. Report no. 10-EHC002-EF.
27. Catanzaro DF, Frishman WH,. Angiotensin receptor blockers for management of hypertension. South Med J. 2010; 103: 669-673.